Poster

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Discover how active learning and Bayesian optimization improve virtual population generation for quantitative systems pharmacology…

Certara2026 年 6 月 18 日

Webinar

Building IND-Ready and Investor-Ready Development Programs

Certara2026 年 6 月 15 日

Poster

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…

Certara2026 年 6 月 9 日

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

Certara2026 年 6 月 9 日

Blog

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

Certara2026 年 6 月 9 日

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-Bodnar2026 年 5 月 28 日

Publication

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

Certara2026 年 5 月 21 日

On-Demand Webinar

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Learn how Phoenix NLME and RsNLME support advanced PK/PD workflows and complex pharmacometric modeling through…

Certara2026 年 5 月 20 日

Webinar

Minimize risk when preparing for hepatic impairment studies

Certara2026 年 5 月 12 日

On-Demand Webinar

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

See how Phoenix NLME and RsNLME support scalable and manageable workflows as project demands evolve.

Danielle Pillsbury2026 年 5 月 8 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

临床药理学

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Building IND-Ready and Investor-Ready Development Programs

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Minimize risk when preparing for hepatic impairment studies

Pharmacometrics Under Pressure Part 2 – The Steady Miles: Project-Grade PMx Without Losing Pace

订阅时事通讯

快捷链接

解决方案

联系我们